The DOI matches its Crossref record; 97 of the 97 references it cites were found in a registry or an index.
Therapeutic Drug Monitoring in the Treatment of Tuberculosis: An Update
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.167.4.603 · Cited by 1,944
(2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.161.4.16141 · Cited by 1,525
Kaplan, J. E., Benson, C., Holmes, K. K., Brooks, J. T., Pau, A., & Masur, H. (2009) · PsycEXTRA Dataset · doi:10.1037/e537722009-001 · Cited by 1,343
Three Months of Rifapentine and Isoniazid for Latent Tuberculosis Infection
Sterling, T. R., Villarino, M. E., Borisov, A. S., Shang, N., Gordin, F., Bliven-Sizemore, E., Hackman, J., Hamilton, C. D., Menzies, D., Kerrigan, A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104875 · Cited by 977
Tuberculosis and diabetes mellitus: convergence of two epidemics
Dooley, K. E., & Chaisson, R. E. (2009) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(09)70282-8 · Cited by 932
Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection
(2016) · Pediatric Clinical Practice Guidelines & Policies · doi:10.1542/9781610020190-part06-targeted · Cited by 920
Fox, W., Ellard, G. A., & Mitchison, D. A. (1999) · PubMed · Cited by 797
Enteropathy Associated with the Acquired Immunodeficiency Syndrome
KOTLER, D. P., GAETZ, H. P., LANGE, M., KLEIN, E. B., & HOLT, P. R. (1984) · Annals of Internal Medicine · doi:10.7326/0003-4819-101-4-421 · Cited by 592
The curious characteristics of pyrazinamide: a review.
Zhang, Y., & Mitchison, D. A. (2003) · PubMed · Cited by 586
M. tuberculosis persistence, latency, and drug tolerance
Gomez, J. E., & McKinney, J. D. (2004) · Tuberculosis · doi:10.1016/j.tube.2003.08.003 · Cited by 533
Dried Blood Spot Methods in Therapeutic Drug Monitoring: Methods, Assays, and Pitfalls
Edelbroek, P. M., Heijden, J. V. D., & Stolk, L. M. L. (2009) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0b013e31819e91ce · Cited by 512
Tuberculosis: Latency and Reactivation
Flynn, J. L., & Chan, J. (2001) · Infection and Immunity · doi:10.1128/iai.69.7.4195-4201.2001 · Cited by 500
(2000) · PubMed · Cited by 486
Zhang, Y. (2003) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkg446 · Cited by 477
The Clinical Pharmacokinetics of Levofloxacin
Fish, D. N., & Chow, A. T. (1997) · Clinical Pharmacokinetics · doi:10.2165/00003088-199732020-00002 · Cited by 475
Therapeutic Drug Monitoring in the Treatment of Tuberculosis
Peloquin, C. A. (2002) · Drugs · doi:10.2165/00003495-200262150-00001 · Cited by 446
Self-citationSerum Drug Concentrations Predictive of Pulmonary Tuberculosis Outcomes
Pasipanodya, J. G., McIlleron, H., Burger, A., Wash, P. A., Smith, P., & Gumbo, T. (2013) · Journal of Infectious Diseases · doi:10.1093/infdis/jit352 · Cited by 444
Sotgiu, G., Centis, R., D'Ambrosio, L., Alffenaar, J.-W. C., Anger, H. A., Caminero, J. A., Castiglia, P., De Lorenzo, S., Ferrara, G., Koh, W.-J., et al. (2012) · European Respiratory Journal · doi:10.1183/09031936.00022912 · Cited by 416
Hernández-Pando, R., Jeyanathan, M., Mengistu, G., Aguilar, D., Orozco, H., Harboe, M., Rook, G., & Bjune, G. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03493-0 · Cited by 406
Alisjahbana, B., Sahiratmadja, E., Nelwan, E. J., Purwa, A. M., Ahmad, Y., Ottenhoff, T. H. M., Nelwan, R. H. H., Parwati, I., Meer, J. W. M. V. D., & Crevel, R. V. (2007) · Clinical Infectious Diseases · doi:10.1086/519841 · Cited by 374
Somoskovi, A., Parsons, L. M., & Salfinger, M. (2001) · Respiratory Research · doi:10.1186/rr54 · Cited by 373
Concentration-Dependent Mycobacterium tuberculosis Killing and Prevention of Resistance by Rifampin
Gumbo, T., Louie, A., Deziel, M. R., Liu, W., Parsons, L. M., Salfinger, M., & Drusano, G. L. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01533-06 · Cited by 345
Comparative Pharmacokinetics and Pharmacodynamics of the Rifamycin Antibacterials
Burman, W. J., Gallicano, K., & Peloquin, C. (2001) · Clinical Pharmacokinetics · doi:10.2165/00003088-200140050-00002 · Cited by 337
Self-citationPharmacokinetics-Pharmacodynamics of Rifampin in an Aerosol Infection Model of Tuberculosis
Jayaram, R., Gaonkar, S., Kaur, P., Suresh, B. L., Mahesh, B. N., Jayashree, R., Nandi, V., Bharat, S., Shandil, R. K., Kantharaj, E., et al. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.7.2118-2124.2003 · Cited by 335
Rustomjee, R., Lienhardt, C., Kanyok, T. P., Davies, G., Levin, J., Mthiyane, T., Reddy, C., Sturm, A. W., Sirgel, F. A., Allen, J., et al. (2008) · PubMed · Cited by 326
Role of individual drugs in the chemotherapy of tuberculosis.
Mitchison, D. A. (2000) · PubMed · Cited by 319
Gumbo, T., Louie, A., Deziel, M. R., Parsons, L. M., Salfinger, M., & Drusano, G. L. (2004) · The Journal of Infectious Diseases · doi:10.1086/424849 · Cited by 315
Rayner, C. R., Forrest, A., Meagher, A. K., Birmingham, M. C., & Schentag, J. J. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342150-00007 · Cited by 306
In Vivo Pharmacodynamics of a New Oxazolidinone (Linezolid)
Andes, D., van Ogtrop, M. L., Peng, J., & Craig, W. A. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.11.3484-3489.2002 · Cited by 278
Pharmacogenetics-based tuberculosis therapy research group, Azuma, J., Ohno, M., Kubota, R., Yokota, S., Nagai, T., Tsuyuguchi, K., Okuda, Y., Takashima, T., Kamimura, S., et al. (2013) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-012-1429-9 · Cited by 278
Zimhony, O., Cox, J. S., Welch, J. T., Vilchèze, C., & Jacobs, W. R. (2000) · Nature Medicine · doi:10.1038/79558 · Cited by 270
Dorman, S. E., Johnson, J. L., Goldberg, S., Muzanye, G., Padayatchi, N., Bozeman, L., Heilig, C. M., Bernardo, J., Choudhri, S., Grosset, J. H., et al. (2009) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200901-0078oc · Cited by 264
Location of Persisting Mycobacteria in a Guinea Pig Model of Tuberculosis Revealed by R207910
Lenaerts, A. J., Hoff, D., Aly, S., Ehlers, S., Andries, K., Cantarero, L., Orme, I. M., & Basaraba, R. J. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00276-07 · Cited by 257
Impact of Diabetes Mellitus on Treatment Outcomes of Patients with Active Tuberculosis
Dooley, K. E., Tang, T., Golub, J. E., Dorman, S. E., & Cronin, W. (2009) · The American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.2009.80.634 · Cited by 256
Ohno, M., Yamaguchi, I., Yamamoto, I., Fukuda, T., Yokota, S., Maekura, R., Ito, M., Yamamoto, Y., Ogura, T., Maeda, K., et al. (2000) · PubMed · Cited by 251
Pasipanodya, J. G., Srivastava, S., & Gumbo, T. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis353 · Cited by 239
Mycobacterium avium Complex Infection
Young, L. S. (1988) · Journal of Infectious Diseases · doi:10.1093/infdis/157.5.863 · Cited by 236
Weiner, M., Benator, D., Burman, W., Peloquin, C. A., Khan, A., Vernon, A., Jones, B., Silva-Trigo, C., Zhao, Z., Hodge, T., et al. (2005) · Clinical Infectious Diseases · doi:10.1086/429321 · Cited by 226
Self-citationDurant, J., Clevenbergh, P., Garraffo, R., Halfon, P., Icard, S., Giudice, P. D., Montagne, N., Schapiro, J. M., & Dellamonica, P. (2000) · AIDS · doi:10.1097/00002030-200007070-00005 · Cited by 220
GILLIN, J. S., SHIKE, M., ALCOCK, N., URMACHER, C., KROWN, S., KURTZ, R. C., LIGHTDALE, C. J., & WINAWER, S. J. (1985) · Annals of Internal Medicine · doi:10.7326/0003-4819-102-5-619 · Cited by 219
Diacon, A. H., Patientia, R. F., Venter, A., van Helden, P. D., Smith, P. J., McIlleron, H., Maritz, J. S., & Donald, P. R. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01474-06 · Cited by 193
Peloquin, C. A., Hadad, D. J., Molino, L. P. D., Palaci, M., Boom, W. H., Dietze, R., & Johnson, J. L. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01036-07 · Cited by 185
Self-citationPharmacokinetics of Rifampin Under Fasting Conditions, With Food, and With Antacids
Peloquin, C. A., Namdar, R., Singleton, M. D., & Nix, D. E. (1999) · Chest · doi:10.1378/chest.115.1.12 · Cited by 178
Self-citationCho, H.-J., Koh, W.-J., Ryu, Y.-J., Ki, C.-S., Nam, M.-H., Kim, J.-W., & Lee, S.-Y. (2007) · Tuberculosis · doi:10.1016/j.tube.2007.05.012 · Cited by 173
Effect of Diabetes Mellitus on Pharmacokinetic and Pharmacodynamic Properties of Drugs
Dostálek, M., Akhlaghi, F., & Puzanovova, M. (2012) · Clinical Pharmacokinetics · doi:10.1007/bf03261926 · Cited by 171
Low Serum Antimycobacterial Drug Levels in Non-HIV-Infected Tuberculosis Patients
Kimerling, M. E., Phillips, P., Patterson, P., Hall, M., Robinson, C. A., & Dunlap, N. E. (1998) · Chest · doi:10.1378/chest.113.5.1178 · Cited by 170
Rifampicin Reduces Plasma Concentrations of Moxifloxacin in Patients with Tuberculosis
Nijland, H. M. J., Ruslami, R., Suroto, A. J., Burger, D. M., Alisjahbana, B., van Crevel, R., & Aarnoutse, R. E. (2007) · Clinical Infectious Diseases · doi:10.1086/521894 · Cited by 166
Park, I.-N. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl298 · Cited by 161
Low Antituberculosis Drug Concentrations in Patients with AIDS
Peloquin, C. A., Nitta, A. T., Burman, W. J., Brudney, K. F., Miranda-Massari, J. R., McGuinness, M. E., Berning, S. E., & Gerena, G. T. (1996) · Annals of Pharmacotherapy · doi:10.1177/106002809603000901 · Cited by 158
Self-citationDémolis, J. (2000) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2000.111482 · Cited by 155
Heysell, S. K., Moore, J. L., Keller, S. J., & Houpt, E. R. (2010) · Emerging infectious diseases · doi:10.3201/eid1610.100374 · Cited by 154
Burman, W. J., Gallicano, K., & Peloquin, C. A. (1999) · Clinical Infectious Diseases · doi:10.1086/515174 · Cited by 152
Self-citationDrug Susceptibility in the Chemotherapy of Mycobacterial Infections
Heifets, L. B., & Cynamon, M. H. (1991) · Cited by 151
Pharmacokinetic and Pharmacodynamic Issues in the Treatment of Mycobacterial Infections
Nuermberger, E. L., & Grosset, J. H. E. (2004) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-004-1109-5 · Cited by 140
Papastavros, T., Dolovich, L. R., Holbrook, A. M., et al. (2002) · PubMed · Cited by 126
Malabsorption of Antimycobacterial Medications
Peloquin, C. A., MacPhee, A. A., & Berning, S. E. (1993) · New England Journal of Medicine · doi:10.1056/nejm199310073291513 · Cited by 119
Self-citationPasipanodya, J. G., & Gumbo, T. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00749-10 · Cited by 118
Higher-dose rifampin for the treatment of pulmonary tuberculosis: a systematic review.
Steingart, K. R., Jotblad, S., Robsky, K., Deck, D. H., Hopewell, P. C., Huang, D., & Nahid, P. (2011) · PubMed · Cited by 112
Fluoroquinolones for the Treatment of Pulmonary Tuberculosis
Moadebi, S., Harder, C. K., Fitzgerald, M. J., Elwood, K., & Marra, F. (2007) · Drugs · doi:10.2165/00003495-200767140-00007 · Cited by 110
USING THERAPEUTIC DRUG MONITORING TO DOSE THE ANTIMYCOBACTERIAL DRUGS
Peloquin, C. A. (1997) · Clinics in Chest Medicine · doi:10.1016/s0272-5231(05)70357-9 · Cited by 107
Self-citationEffects of Rifampin and Multidrug Resistance Gene Polymorphism on Concentrations of Moxifloxacin
WEINER, M. H., Burman, W. J., Luo, C.-C., et al. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01621-06 · Cited by 106
Demczar, D. J., Nafziger, A. N., & Bertino, J. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.5.1115 · Cited by 101
Boulanger, C., Hollender, E. S., Farrell, K., Stambaugh, J. J., Maasen, D., Ashkin, D., Symes, S. N., Espinoza, L. A., Rivero, R. O., Graham, J. J., et al. (2009) · Clinical Infectious Diseases · doi:10.1086/606056 · Cited by 100
Self-citationHwang, T. J., Wares, D. F., Jafarov, A., Jakubowiak, W., Nunn, P., & Keshavjee, S. A. (2013) · The International Journal of Tuberculosis and Lung Disease · doi:10.5588/ijtld.12.0863 · Cited by 100
Singapore, T. S. B. M. (1981) · Tubercle · doi:10.1016/0041-3879(81)90016-7 · Cited by 92
Narita, M., Stambaugh, J. J., Hollender, E. S., Jones, D., Pitchenik, A. E., & Ashkin, D. (2000) · Clinical Infectious Diseases · doi:10.1086/313771 · Cited by 89
Hafner, R., Bethel, J., Power, M. E., et al. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.3.631 · Cited by 85
Pharmacological Issues in the Treatment of Tuberculosis
PELOQUIN, C. A. (2001) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2001.tb11374.x · Cited by 82
Self-citationVu, D. H., Bolhuis, M. S., Koster, R. A., Greijdanus, B., de Lange, W. C. M., van Altena, R., Brouwers, J. R. B. J., Uges, D. R. A., & Alffenaar, J. C. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01054-12 · Cited by 82
Evaluation of moxifloxacin for the treatment of tuberculosis: 3 years of experience
Pranger, A. D., van Altena, R., Aarnoutse, R. E., van Soolingen, D., Uges, D. R. A., Kosterink, J. G. W., van der Werf, T. S., & Alffenaar, J. C. (2011) · European Respiratory Journal · doi:10.1183/09031936.00176610 · Cited by 81
Mahmoud, L. B., Ghozzi, H., Kamoun, A., Hakim, A., Hachicha, H., Hammami, S., Sahnoun, Z., Zalila, N., Makni, H., & Zeghal, K. M. (2011) · Pathologie Biologie · doi:10.1016/j.patbio.2011.07.001 · Cited by 80
The Effect of Hemodialysis on Isoniazid, Rifampin, Pyrazinamide, and Ethambutol
Malone, R. S., Fish, D. N., Spiegel, D. M., CHILDS, J. M., & Peloquin, C. A. (1999) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.159.5.9810034 · Cited by 76
Self-citationComparison of Levofloxacin versus Moxifloxacin for Multidrug-Resistant Tuberculosis
Koh, W., Lee, S. H., Kang, Y. A., Lee, C., Choi, J. C., Lee, J. H., Jang, S. H., Yoo, K. H., Jung, K. H., Kim, K. U., et al. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201303-0604oc · Cited by 71
Alffenaar, J. C., van Altena, R., Harmelink, I. M., Filguera, P., Molenaar, E., Wessels, A. M. A., van Soolingen, D., Kosterink, J. G. W., Uges, D. R. A., & van der Werf, T. S. (2010) · Clinical Pharmacokinetics · doi:10.2165/11532080-000000000-00000 · Cited by 67
Pasipanodya, J. G., & Gumbo, T. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01567-09 · Cited by 67
Using Animal Models to Develop New Treatments for Tuberculosis
Nuermberger, E. L. (2008) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0028-1085705 · Cited by 66
Therapeutic drug monitoring in the treatment of tuberculosis patients
Magis-Escurra, C., van den Boogaard, J., IJdema, D., Boeree, M. J., & Aarnoutse, R. E. (2011) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2011.12.001 · Cited by 63
Dooley, K. E., Flexner, C. W., Hackman, J., et al. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00554-08 · Cited by 62
Ahmad, Z., Fraig, M., Bisson, G. P., Nuermberger, E. L., Grosset, J. H. E., & Karakousis, P. C. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01524-10 · Cited by 54
Tam, C. M., Chan, S. L., Kam, K. M., Goodall, R. L., & Mitchison, D. A. (2002) · PubMed · Cited by 54
Narita, M., Hisada, M., Thimmappa, B., et al. (2001) · Clinical Infectious Diseases · doi:10.1086/318490 · Cited by 53
Once-Daily and Twice-Daily Dosing of p-Aminosalicylic Acid Granules
Peloquin, C. A., Berning, S. E., Huitt, G. A., et al. (1999) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.159.3.9807131 · Cited by 51
Self-citationLou, H., Shullo, M. A., & McKaveney, T. P. (2002) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.22.9.701.34065 · Cited by 51
Heysell, S. K., Moore, J. L., Staley, D., Dodge, D., & Houpt, E. R. (2013) · Tuberculosis Research and Treatment · doi:10.1155/2013/129723 · Cited by 45
Pharmacokinetics and pharmacodynamics in the development of anti-tuberculosis drugs
Davies, G., & Nuermberger, E. L. (2008) · Tuberculosis · doi:10.1016/s1472-9792(08)70037-4 · Cited by 44
Ellard, G. A., & Fourie, P. B. (1999) · PubMed · Cited by 42
Fluoroquinolones for treating tuberculosis (presumed drug-sensitive)
Ziganshina, L. E., Титаренко, А. Ф., & Davies, G. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004795.pub4 · Cited by 41
Use of Therapeutic Drug Monitoring for Multidrug-Resistant Tuberculosis Patients
Li, J., Burzynski, J. N., Lee, Y.-A., Berg, D. E., Driver, C. R., Ridzon, R., & Munsiff, S. S. (2004) · CHEST Journal · doi:10.1378/chest.126.6.1770 · Cited by 39
Mycobacterium avium Complex Infection
Peloquin, C. A. (1997) · Clinical Pharmacokinetics · doi:10.2165/00003088-199732020-00004 · Cited by 38
Self-citationHu, H., WU, C. Y., Huang, N., Chou, Y., Chang, Y.-C., & CHU, D. (2013) · Epidemiology and Infection · doi:10.1017/s0950268813000551 · Cited by 37
The Effect of Hemodialysis on Cycloserine, Ethionamide, Para-Aminosalicylate, and Clofazimine
Malone, R. S., Fish, D. N., Spiegel, D. M., et al. (1999) · CHEST Journal · doi:10.1378/chest.116.4.984 · Cited by 32
Rekindling old controversy on elusive lair of latent tuberculosis
Bishai, W. R. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03485-1 · Cited by 28
Concomitant Use of Voriconazole and Rifabutin in a Patient with Multiple Infections
Schwiesow, J. N., Iseman, M. D., & Peloquin, C. A. (2008) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.28.8.1076 · Cited by 28
Self-citationAndries, A., Isaakidis, P., Das, M., Khan, S., Paryani, R., Desai, C., Dalal, A., Mansoor, H., Verma, R., Fernandes, D., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0078313 · Cited by 27 · cited 1×
“As with PAS, and especially if the two drugs are used together, patients should be monitored for hypothyroidism [146].”
Tuberculosis Drug Serum Levels
Peloquin, C. A. (2001) · Clinical Infectious Diseases · doi:10.1086/322706 · Cited by 24
Self-citationAntituberculosis therapy for 2012 and beyond
Lauzardo, M., & Peloquin, C. A. (2012) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2012.657176 · Cited by 24
Self-citationBenator, D., WEINER, M. H., Burman, W. J., et al. (2007) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.27.6.793 · Cited by 17
Cited by
Pai, M., Behr, M. A., Dowdy, D., Dheda, K., Divangahi, M., Boehme, C. C., Ginsberg, A., Swaminathan, S., Spigelman, M., Getahun, H., et al. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.76 · Cited by 1,270
Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline
Nahid, P., Mase, S. R., Migliori, G. B., Sotgiu, G., Bothamley, G. H., Brozek, J. L., Cattamanchi, A., Cegielski, J. P., Chen, L., Daley, C. L., et al. (2019) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201909-1874st · Cited by 462
Self-citationCaraux-Paz, P., Diamantis, S., de Wazières, B., & Gallien, S. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10245888 · Cited by 174
Peloquin, C. A., Dorman, S. E., Vernon, A., Battista Migliori, G., & Nahid, P. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/ciw679 · Cited by 6
Self-citation
Metadata
- Authors
- Alsultan, A., & Peloquin, C. A.
- Venue
- Drugs
- Published
- 2014-05-21
- Volume
- 74
- Issue
- 8
- Pages
- 839-854
- ISSN
- 0012-6667 (ISSN-L)
- 1179-1950
- OpenAlex
- W2027951201
- Cited by
- 444
- References
- 97
- FWCI
- 23.80
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.